Adamas Pharmaceuticals Inc.

NASDAQ: ADMSHealthcare / Drugs - Generic / USA
7.33+0.5800+8.59%Vol 1 375 6391Y Perf -62.91%
Sep 20th, 2019 16:00
BID7.01 ASK7.30
Open6.74 Previous Close6.75
Pre-Market- After-Trading7.30
 - -%  -0.03 -0.41%
Target Price
12.63 
Analyst Rating
Moderate Buy 2.20
Potencial %
72.31 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12M
-100/-100/-73 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-100/-100/-36 
Growth Ranking
★★+     47.45
Insiders Shares Cnt. % 3/6/12M
-100/-100/-54 
Income Ranking
 —    -
Market Cap (mil)204 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
19.05 
Earnings Date
7th Nov 2019

Today's Price Range

6.747.41

52wk Range

4.2020.63

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
15.80%
1 Month
19.38%
3 Months
33.27%
6 Months
-8.26%
1 Year
-62.91%
3 Years
-58.84%
5 Years
-58.59%
10 Years
-

Name / TickerPriceChg.Chg.%
ADMS7.330.58008.59
AAPL217.73-3.2300-1.46
GOOG1 229.93-8.7800-0.71
MSFT139.44-1.6300-1.16
XOM72.08-0.2500-0.35
WFC48.63-0.2800-0.57
JNJ131.651.54001.18
FB189.93-0.2100-0.11
GE9.37-0.0500-0.53
JPM118.90-0.4800-0.40
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.98-0.908.16
Q01 2019-1.13-1.084.42
Q04 2018-1.36-1.0622.06
Q03 2018-1.34-1.228.96
Q02 2018-1.41-1.2610.64
Q01 2018-1.38-1.352.17
Q04 2017-1.15-1.27-10.43
Q03 2017-1.03-1.04-0.97
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.894.30Positive
12/2019 QR-0.842.33Positive
12/2019 FY-3.633.71Positive
12/2020 FY-2.324.13Positive
Next Report Date7th Nov 2019
Estimated EPS Next Report-0.89
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1 375 639
Shares Outstanding (in ths.)27 771
Trades Count3 634
Dollar Volume5 157 781
Avg. Volume467 862
Avg. Weekly Volume1 115 215
Avg. Monthly Volume615 154
Avg. Quarterly Volume415 512
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (50.00 %)
5 (55.56 %)
5 (55.56 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (40.00 %)
3 (33.33 %)
3 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (10.00 %)
1 (11.11 %)
1 (11.11 %)
RatingModerate Buy
2.20
Moderate Buy
2.11
Moderate Buy
2.11

Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

CEO: Gregory T. Went

Teplephone: +1 510 450-3500

Address: 1900 Powell Street, Emeryville 94608, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

38%63%

Bearish Bullish

49%51%

News